首页> 美国卫生研究院文献>Journal of Antimicrobial Chemotherapy >Serum and cellular ribavirin pharmacokinetic and concentration–effect analysis in HCV patients receiving sofosbuvir plus ribavirin

【2h】

Serum and cellular ribavirin pharmacokinetic and concentration–effect analysis in HCV patients receiving sofosbuvir plus ribavirin

机译：接受索非布韦联合利巴韦林治疗的HCV患者的血清和细胞利巴韦林药代动力学及浓度效应分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectivesRibavirin concentrations may impact hepatitis C virus (HCV) treatment outcome. We modelled ribavirin serum and intracellular ribavirin monophosphate (RBV-MP) and ribavirin triphosphate (RBV-TP) pharmacokinetics in red blood cells (RBC) using samples collected during the NIAID SPARE trial to explore associations with treatment outcome and the development of anaemia.

机译：目的利巴韦林浓度可能会影响丙型肝炎病毒（HCV）的治疗结果。我们使用NIAID SPARE试验期间收集的样本对利巴韦林血清，细胞内利巴韦林单磷酸（RBV-MP）和细胞内利巴韦林三磷酸（RBV-TP）药代动力学建模，以探讨与治疗结果和贫血发展的关系。

著录项

期刊名称 Journal of Antimicrobial Chemotherapy
作者
Joseph E. Rower; Eric G. Meissner; Leah C. Jimmerson; Anu Osinusi; Zayani Sims; Tess Petersen; Lane R. Bushman; Pamela Wolfe; John G. McHutchison; Shyamasundaran Kottilil; Jennifer J. Kiser;
展开▼
作者单位

展开▼
年(卷),期 -1(70),8
年度 -1
页码 2322–2329
总页数 8
原文格式 PDF
正文语种
中图分类药学;微生物学;病毒传染病;
关键词
ribavirin monophosphate anaemia SVR interferon-free therapy red blood cells;

机译：利巴韦林单磷酸盐;贫血;SVR;无干扰素治疗;红细胞;

相似文献

外文文献
中文文献
专利

1. Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin [J] . Rower Joseph E., Meissner Eric G., Jimmerson Leah C., The Journal of Antimicrobial Chemotherapy . 2015,第8期

机译：接受索非布韦+利巴韦林治疗的HCV患者的血清和细胞利巴韦林药代动力学和浓度效应分析
2. The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin [J] . Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie . 2020,第期

机译：遗传变异对HCV-4埃及患者接受Sofosbuvir / daclatasvir和利巴韦林的HCV-4埃及患者治疗反应的影响
3. Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin [J] . Agarwal Kosh, Schultz Michael, Pianko Stephen, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：Sofosbuvir Plus Peginterferon Plus利韦利林在基因型中为12周，3个HCV感染患者和治疗经验丰富的肝硬化患者2 HCV在Sofosbuvir Plus利巴韦林的16或24周后没有达到SVR
4. HCV-related Factors but not HIV-Related Factors at Baseline Predict the Response to Treatment With Peginterferon alfa-2a (40KD) (PEGASYS) Plus Ribavirin (COPEGUS) in Patients With HCV/HIV Co-infection: Predictor Analysis From the APRICOT Study [C] . D. Cooper, F.J. Torriani, M. Rodriguez Torres International AIDS Conference . 2004

机译：HCV相关因素但基线上没有艾滋病毒相关因素预测与HCV / HIV共感染患者的Peginterferon Alfa-2a（40kd）（Pegasys）（Pegasys）加利巴韦林（Copegus）对治疗的反应：来自杏研究的预测因素分析
5. Population pharmacokinetics and efficacy of ribavirin in patients with chronic hepatitis C genotype 1 infection. [D] . Jin, Runyan. 2010

机译：利巴韦林在慢性丙型肝炎基因型1感染患者中的群体药代动力学和功效。
6. Early Ribavirin Pharmacokinetics HCV RNA and Alanine Aminotransferase Kinetics in HIV/HCV Co-infected Patients During Treatment with Pegylated Interferon and Ribavirin [O] . Harel Dahari, Marianthi Markatou, Marija Zeremski, -1

机译：聚乙二醇干扰素和利巴韦林治疗期间HIV / HCV合并感染患者的早期利巴韦林药代动力学HCV RNA和丙氨酸氨基转移酶动力学
7. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials [O] . Jason Grebely, Stefan Mauss, Ashley Brown, 2016

机译：雷普斯韦尔/索福斯蟾与无利用素患者慢性HCV基因型1感染接受阿片类药物替代治疗的疗效和安全性：分析3阶段离子试验

Serum and cellular ribavirin pharmacokinetic and concentration–effect analysis in HCV patients receiving sofosbuvir plus ribavirin

摘要

著录项

相似文献

相关主题

期刊订阅